Últimas noticias sobre Aprea Therapeutics (NASDAQ:APRE) Bolsa

Aprea Therapeutics

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.

Aprea Therapeutics Inc

Aprea Therapeutics ( ($APRE) ) just unveiled an announcement. Aprea Therapeutics has announced promising preliminary safety results for its WEE1 in...

Aprea Therapeutics Reports Promising Results for APR-1051 Trials

Aprea Therapeutics falls on data from APR-1051 study in cancer-associated gene alterations

In a report released yesterday, Jason McCarthy from Maxim Group reiterated a Buy rating on Aprea Therapeutics (APRE – Research Report), with a pric...

Promising Safety and Financial Strength Propel Buy Rating for Aprea Therapeutics

Aprea Therapeutics GAAP EPS of -$0.64

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Aprea Therapeutics (APRE – Research Report), with a pric...

Buy Recommendation for Aprea Therapeutics Based on Promising Clinical Progress and Strategic Financial Positioning

H.C. Wainwright analyst Joseph Pantginis has reiterated their bullish stance on APRE stock, giving a Buy rating on November 7. Joseph Pantginis has...

Aprea Therapeutics: Buy Rating Driven by Clinical Progress and Financial Stability

Aprea Therapeutics (APRE) announced that the first patient has been dosed at Dose Level 7, evaluating ATRN-119 550 mg twice daily, in the ongoing A...

Aprea Therapeutics announces first patient dosed in ABOYA-119 Phase 1/2a trial

Aprea Therapeutics' Promising ATRN-119: A Buy Rating Amid Optimized Dosing and Safety Advancements

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Aprea Therapeutics (APRE – Research Report) today and set a price target of $20...

Promising Clinical Advances Drive Buy Rating for Aprea Therapeutics

Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Aprea Therapeutics (APRE – Research Report) and keeping the price target a...

Strategic Advancements and Financial Stability Drive Buy Rating for Aprea Therapeutics

APRE

News

Health Care

Press Releases

UPDATE - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

Aprea Therapeutics to Present at the Life Sciences Investor Forum on September 19

Aprea Therapeutics to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024

Halda Therapeutics Appoints Veteran Biopharma Leader, Christian Schade, as President and Chief Executive Officer

Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development

Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit

Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

Earnings

Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward

IART

OMGA

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics

Cardio Diagnostics Holdings Inc. - Common stock

Cardio Diagnostics Hldgs

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics

CervoMed

Cyclo Therapeutics

Eterna Therapeutics

Evaxion Biotech A/S - American Depositary Share

Comments

Aprea Therapeutics

Noticias

Últimas noticias sobre Aprea Therapeutics (NASDAQ:APRE) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL